Tau Protein Phosphorylation-IN-1

Tau Protein Phosphorylation-IN-1 是一种 tau 蛋白 (tau protein) 磷酸化抑制剂,能有效保护 PC12 细胞免受 Aβ25-35 诱导的细胞毒性 (EC50 = 1.93 μM),并能穿透血脑屏障,在体外和体内均能逆转 tau 蛋白的过度磷酸化,显著抑制免疫相关细胞毒性因子的表达,阻断 MAPK 和 NF-κB 信号通路,并显著降低 RAGE 及凋亡 (apoptosis) 因子 Bax/Bcl-2 的表达水平,同时在阿尔茨海默病小鼠模型中可减轻小鼠的神经损伤并改善其学习记忆能力,因此适用于阿尔茨海默病的相关研究。
产品编号: MS-S21384 CAS No.: 3075165-36-2 分子式: C39H56N4O3 分子量: 628.89
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

Tau Protein Phosphorylation-IN-1 是一种 tau 蛋白 (tau protein) 磷酸化抑制剂,能有效保护 PC12 细胞免受 Aβ25-35 诱导的细胞毒性 (EC50 = 1.93 μM),并能穿透血脑屏障,在体外和体内均能逆转 tau 蛋白的过度磷酸化,显著抑制免疫相关细胞毒性因子的表达,阻断 MAPK 和 NF-κB 信号通路,并显著降低 RAGE 及凋亡 (apoptosis) 因子 Bax/Bcl-2 的表达水平,同时在阿尔茨海默病小鼠模型中可减轻小鼠的神经损伤并改善其学习记忆能力,因此适用于阿尔茨海默病的相关研究。

生物实验数据

生物活性 Tau Protein Phosphorylation-IN-1 is a tau protein phosphorylation inhibitor that effectively protects PC12 cells from Aβ25-35-induced cytotoxicity (EC50 = 1.93 μM) and can penetrate the blood-brain barrier; it reverses tau hyperphosphorylation both in vitro and in vivo, significantly inhibits the expression of immune-related cytotoxic factors, blocks the MAPK and NF-κB signaling pathways, and markedly reduces the expression levels of RAGE and the apoptosis factor Bax/Bcl-2, while in Alzheimer's disease mouse models it alleviates neuronal damage and improves learning and memory abilities, making it suitable for research related to Alzheimer's disease.
体外研究
(In Vitro)

Tau Protein Phosphorylation-IN-1 (compound B1) (24 小时) 在 30 μM 浓度下对 PC12 细胞无毒性,在 10 μM 浓度下能显著抵抗 Aβ25-35 诱导的细胞毒性。
Tau Protein Phosphorylation-IN-1 (2.5-10 μM,24 小时) 在 Aβ25-35 诱导的 PC12 细胞中通过多重机制表现出神经保护作用,包括显著降低 Thr181、 Thr205 和 Ser396 位点的 tau 磷酸化水平,抑制 MAPKs (p38、ERK、JNK) 和 NF-κB 的磷酸化,逆转 Aβ 诱导的 iNOS 和 COX-2 表达上调,调控凋亡相关蛋白 Bax/Bcl-2 的表达并抑制 RAGE。

Western Blot Analysis

Cell Line: PC12 cells
Concentration: 2.5, 5 and 10 μM
Incubation Time: 24 h
Result: Decreased phosphorylated tau levels at Thr181, Thr205, and Ser396 sites caused by Aβ25–35 compared to the model group.
Exhibited stronger inhibition of tau phosphorylation at the Thr181, Thr205, and Ser396 sites than Oleanolic acid (OA)(MS-L65784) or Donepezil (MS-W27801) at 10 μM.
Reversed the Aβ25–35-induced upregulation of iNOS and COX-2 levels.
Significantly inhibited RAGE expression at 5 and 10 μM.
Decreased Bax and Bcl-2 expression compared to the control group.
Inhibited the phosphorylation of p38 MAPK, ERK and JNK, thereby blocking the MAPK signaling pathway.
Reduced the expression of p-NF-κB in Aβ25–35-induced PC12 cells.
体内研究
(In Vivo)

Tau Protein Phosphorylation-IN-1 (2.5、5 和 10 mg/kg,腹腔注射,每日一次,持续 28 天) 能够改善阿尔茨海默病小鼠模型中小鼠的认知缺陷,减轻 tau 蛋白过度磷酸化,并抑制神经炎症。

Animal Model: Male ICR mice (20-22 g) intracerebroventricularly injected with Aβ₂₅–₃₅ solution (9 nmol/3 μL/mouse)
Dosage: 2.5, 5 and 10 mg/kg
Administration: i.p., daily for 28 days
Result: Reduced the escape latencies on training days 2-5 compared with the Aβ group in the Morris water maze test.
Increased the number of crossings over the original platform location, in contrast to the significant reduction observed in the Aβ group.
Reversed the Aβ-induced histopathological damage, including irregular neuronal distribution and reduced cell numbers in the hippocampal CA1 and CA3 areas.
Significantly reduced the levels of tau phosphorylation at Thr205, and Ser396 sites, compared with the Aβ group.
Significantly decreased the level of tau phosphorylation at the Thr181 site in the hippocampus, especially in the DG, CA1, and CA3 pyramidal neurons.
Suppressed the Aβ25-35-induced upregulation of iNOS, COX-2, RAGE, and the Bax/Bcl-2 ratio.
Showed an inhibitory effect on p38 MAPK, ERK, and JNK phosphorylation in Aβ25-35-induced AD mice.
Inhibited the Aβ25-35-induced upregulation of NF-κB in a dose-dependent manner.
Caused no histopathological damage in the liver or kidneys at any tested dose (up to 10 mg/kg) over 21 days.

化学信息

分子量 628.89
分子式 C39H56N4O3
CAS No. 3075165-36-2

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础